| Literature DB >> 21408619 |
Cheng-Yuan Kao1, Ferdinand C O Los, Danielle L Huffman, Shinichiro Wachi, Nicole Kloft, Matthias Husmann, Valbona Karabrahimi, Jean-Louis Schwartz, Audrey Bellier, Christine Ha, Youn Sagong, Hui Fan, Partho Ghosh, Mindy Hsieh, Chih-Shen Hsu, Li Chen, Raffi V Aroian.
Abstract
Here we present the first global functional analysis of cellular responses to pore-forming toxins (PFTs). PFTs are uniquely important bacterial virulence factors, comprising the single largest class of bacterial protein toxins and being important for the pathogenesis in humans of many Gram positive and Gram negative bacteria. Their mode of action is deceptively simple, poking holes in the plasma membrane of cells. The scattered studies to date of PFT-host cell interactions indicate a handful of genes are involved in cellular defenses to PFTs. How many genes are involved in cellular defenses against PFTs and how cellular defenses are coordinated are unknown. To address these questions, we performed the first genome-wide RNA interference (RNAi) screen for genes that, when knocked down, result in hypersensitivity to a PFT. This screen identifies 106 genes (∼0.5% of genome) in seven functional groups that protect Caenorhabditis elegans from PFT attack. Interactome analyses of these 106 genes suggest that two previously identified mitogen-activated protein kinase (MAPK) pathways, one (p38) studied in detail and the other (JNK) not, form a core PFT defense network. Additional microarray, real-time PCR, and functional studies reveal that the JNK MAPK pathway, but not the p38 MAPK pathway, is a key central regulator of PFT-induced transcriptional and functional responses. We find C. elegans activator protein 1 (AP-1; c-jun, c-fos) is a downstream target of the JNK-mediated PFT protection pathway, protects C. elegans against both small-pore and large-pore PFTs and protects human cells against a large-pore PFT. This in vivo RNAi genomic study of PFT responses proves that cellular commitment to PFT defenses is enormous, demonstrates the JNK MAPK pathway as a key regulator of transcriptionally-induced PFT defenses, and identifies AP-1 as the first cellular component broadly important for defense against large- and small-pore PFTs.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21408619 PMCID: PMC3048360 DOI: 10.1371/journal.ppat.1001314
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1Genome-wide identification of hpo genes involved in PFT defenses.
(A) Cry5B is a PFT. Representative channel current traces recorded at various holding voltages across a planar lipid bilayer into which activated Cry5B (5–10 µg/mL) was inserted under symmetrical 150 mM KCl conditions. Upwards jumps at +20mV and downwards jumps at −20mV correspond to the current flowing in channels in the open state. Dotted lines (marked “C”) indicate the zero current, corresponding to all channels being in their closed state. Records show large jumps (marked with *), corresponding to a channel conductance of 125 pS, and smaller transitions (marked with #) of about 21 pS that may represent subconductance states of the channel. (B) Flow chart for genome-wide RNAi screening and validation of genes affecting defense to Cry5B. (C) Photographs of typical Hpo hits in the primary screen. Scale bar: 0.5 mm. (D) Venn diagrams illustrating the distribution of common genes between the genome-wide Hpo screen and eight other genome-wide RNAi screens in C. elegans. (E) Putative PFT defense networks assembled from C. elegans interactome databases. Purple circles: previously published hpo genes. Red circles: hpo genes from our RNAi screen. Green circles: other genes connected to hpo genes within the network. Blue lines: known interactions for hpo genes. Grey lines: interactions based on interactome.
RNAi clones that render the animals hypersensitive to Cry5B PFT.
| Sequence name | Gene name | Description | Ortholog and/or Homolog | % Survival on Cry5Bd | % Survival on HEPESe | Double Verification | Cry5B-DEG | |
| G-protein-coupled receptor | ||||||||
| C24B9.7 |
| GPCR | 27 | 93 | ||||
| C51F7.2 |
| GPCR | 7 | 102 | ||||
| F14F8.5 |
| GPCR | 40 | 92 | ||||
| F18E3.6 |
| GPCR | 31 | 95 | ||||
| Y46H3C.1 |
| GPCR | 41 | 99 | ||||
| Ligand and cell surface related | ||||||||
| Y26D4A.2 |
| Cysteine rich domain distantly related to the C-type lectin | 39 | 104 | ||||
| F33D11.9 |
| GPI-anchor attachment protein GAA1 | H. M. D. | 12 | 100 | |||
| T05E11.6 |
| GPI-anchor transamidase | H. M. D. | 13 | 95 | |||
| T14G10.7 |
| GPI-anchor transamidase | H. M. D. | 26 | 102 | |||
| T10D4.4 |
| Insulin-like peptide | 40 | 105 | ||||
| Y41D4B.16 |
| Mucin-3A | H. | 27 | 103 | ▴ | ||
| F11C1.3 |
| Plasma membrane glycoprotein CD36 | H. M. D. | 37 | 99 | ▾ | ||
| Signal transduction | ||||||||
| K11E8.1 |
| Calcium/calmodulin-dependent protein kinase (CaMKII) | H. M. D. | 57 | 100 | |||
| F39H11.3 |
| Cyclin-dependent serine/threonine protein kinase | H. M. D. | 40 | 94 | |||
| Y38C9A.2 |
| GTP-binding protein | H. M. D. | 4 | 98 | |||
| ZK792.6 |
| GTP-binding RAS protooncogene | H. M. D. | 60 | 99 | |||
| T07A9.3 |
| JNK (Jun-N-terminal kinase)-like MAPK | H. M. D. | 20 | 93 | √ | ▴ | |
| ZK470.5 |
| NCK adaptor protein 2 | H. M. D. | 56 | 96 | |||
| B0348.4 |
| Phospholipase C beta | H. M. D. | 23 | 84 | |||
| T17E9.1 |
| Protein serine/threonine kinase | H. M. D. | 40 | 87 | √ | ▴ | |
| F59A6.1 |
| Protein serine/threonine kinase (MAPKKK) | H. M. D. | 48 | 98 | |||
| C40A11.5 |
| Protein tyrosine phosphatase | H. M. | 47 | 85 | |||
| T15B7.2 |
| Protein tyrosine phosphatase | H. M. D. | 51 | 106 | |||
| F42C5.10 |
| Sarcoplasmic reticulum histidine-rich calcium-binding protein | H. | 56 | 98 | √ | ▴ | |
| Y59A8B.23 |
| Ste20-like serine/threonine protein kinase | H. M. D. | 49 | 87 | |||
| F13B10.1 |
| SAM domains and Toll-IL-1 receptor domain | H. M. D. | 48 | 96 | ▴ | ||
| Transcription factor and gene expression | ||||||||
| F29G9.4 |
| AP-1 transcription factor | H. M. D. | 36 | 90 | ▴ | ||
| T24H10.7 |
| AP-1 transcription factor | H. M. D. | 35 | 98 | ▴ | ||
| C05C8.6 |
| BTB/POZ domain | H. M. D. | 32 | 101 | |||
| ZC518.3 |
| CCR4-NOT transcription complex | H. M. D. | 22 | 101 | √ | ||
| VC5.4 |
| Histone acetyltransferase | H. M. D. | 37 | 97 | ▴ | ||
| F01F1.1 |
| Leucine permease transcriptional regulator | H. M. D. | 20 | 102 | |||
| C07D10.2 |
| Meprin-associated Traf homology (MATH) domain | H. M. D. | 16 | 87 | √ | ||
| C49H3.5 |
| MOT2 transcription factor | H. M. D. | 35 | 84 | |||
| T13F3.3 |
| Nuclear hormone receptor | H. M. D. | 43 | 97 | |||
| H37N21.1 |
| Nuclear receptor-binding protein | H. M. D. | 46 | 98 | |||
| ZK1193.5 |
| SATB transcripton factor | H. M. D. | 28 | 83 | |||
| Transporter | ||||||||
| Y54G9A.3 |
| KCNQ-like K+ channel subunits | H. M. D. | 34 | 101 | √ | ||
| C42C1.10 |
| Mitochondrial solute carrier protein | H. M. D. | 17 | 108 | |||
| T24H7.5 |
| P-type ATPase | H. M. D. | 42 | 104 | √ | ▴ | |
| W09C2.3 |
| Plasma membrane Ca2+ ATPase | H. M. D. | 36 | 91 | |||
| R186.5 |
| Voltage-gated K+ channel KCNB/KCNC | H. M. D. | 60 | 92 | √ | ||
| Vesicular trafficking | ||||||||
| C23H4.1 |
| AEX-3 interacting | H. M. D. | 18 | 98 | ▴ | ||
| C37C3.3 |
| Charged multivesicular body protein | H. M. D. | 12 | 92 | |||
| Y65B4A.3 |
| Charged multivesicular body protein | H. M. D. | 22 | 99 | |||
| Y54E10A.2 |
| Conserved oligomeric Golgi complex (COGC) | H. M. D. | 10 | 91 | |||
| Y105E8B.2 |
| Exocyst complex | H. M. D. | 46 | 96 | |||
| Y106G6H.7 |
| Exocyst complex | H. M. D. | 28 | 105 | |||
| T07A5.2 |
| Golgi component Gmh1p | H. M. D. | 29 | 96 | |||
| ZK370.3 |
| Huntingtin-interacting protein | H. M. D. | 29 | 94 | √ | ▴ | |
| VF39H2L.1 |
| SNARE protein | H. M. D. | 19 | 105 | ▴ | ||
| Metabolism | ||||||||
| Y105E8A.10 |
| Bile acid beta-glucosidase | H. M. D. | 27 | 106 | |||
| F59G1.1 |
| Ceramide glucosyltransferase | H. M. D. | 35 | 92 | |||
| C31E10.7 |
| Cytochrome B5 | H. M. D. | 20 | 96 | ▾ | ||
| F28D1.11 |
| Dolichol phosphate mannosyltransferase | H. | 22 | 102 | |||
| Y54E5A.1 |
| Fatty acid desaturase | H. M. D. | 45 | 94 | √ | ▴ | |
| C24G6.6 |
| Flavin-containing amine oxidase | H. M. D. | 51 | 101 | ▾ | ||
| R01H2.5 |
| GDP-L-fucose synthetase | H. M. D. | 33 | 84 | |||
| M02B7.4 |
| Glycosyltransferase | H. M. D. | 12 | 99 | |||
| R10D12.12 |
| Glycosyltransferase | H. M. D. | 58 | 98 | |||
| F41E6.14 |
| Integral membrane O-acyltransferase | 25 | 90 | ||||
| F32D1.2 |
| Mitochondrial F1F0-ATP synthase subunit epsilon | D. | 31 | 104 | ▾ | ||
| F20H11.3 |
| Mitochondrial malate dehydrogenase | H. M. D. | 39 | 102 | ▾ | ||
| ZK353.6 |
| Mitochondrial zinc metalloprotease leucine aminopeptidase | H. M. D. | 48 | 93 | |||
| T05H4.5 |
| NADH-cytochrome B5 reductase | H. M. D. | 53 | 100 | ▾ | ||
| Y47D3A.17 |
| Oxysterol-binding protein | H. M. D. | 6 | 96 | √ | ||
| C10G11.5 |
| Pantothenate kinase | H. M. D. | 38 | 86 | |||
| ZK809.7 |
| PeroxiIsomal membrane protein 3 | H. M. D. | 20 | 101 | |||
| F54F2.8 |
| Peroxisomal farnesylated protein | H. M. D. | 54 | 96 | ▾ | ||
| F39G3.7 |
| Peroxisome assembly factor 2 | H. M. D. | 21 | 100 | |||
| Y110A2AL.12 |
| Phosphatidylinositol-glycan biosynthesis class W protein | H. M. D. | 59 | 99 | |||
| Y37D8A.10 |
| Signal peptidase complex | H. M. D. | 28 | 96 | |||
| C34C6.5 |
| Sphingosine kinase | H. M. D. | 11 | 99 | |||
| Miscellaneous | ||||||||
| M01B12.3 |
| Actin-related protein (Arp)2/3 complex | H. M. D. | 30 | 100 | |||
| Y37D8A.1 |
| Actin-related protein (Arp)2/3 complex | H. M. D. | 25 | 91 | |||
| Y79H2A.6 |
| Actin-related protein (Arp)2/3 complex | H. M. D. | 16 | 85 | |||
| B0024.2 |
| Collagen | H. M. D. | 37 | 100 | |||
| C08B6.7 |
| Dystrophia myotonica-containing WD repeat motif protein | H. M. D. | 49 | 108 | |||
| Y48G8AL.1 |
| E6-AP ubiquitin-protein ligase | H. M. D. | 38 | 99 | |||
| T23D8.7 |
| Eukaryotic translation initiation factor 2C 4 | H. M. D. | 45 | 87 | |||
| F16G10.4 |
| Extracellular protein with cysteine rich structures | 18 | 83 | ||||
| D2024.6 |
| F-actin capping protein alpha subunit | H. M. D. | 42 | 91 | |||
| R09B5.1 |
| F-box protein | 52 | 102 | ||||
| F46E10.11 |
| Fibrillins | H. | 39 | 100 | |||
| C34G6.1 |
| HEAT repeat | H. M. D. | 21 | 90 | |||
| B0336.11 |
| Motile sperm domain | H. M. D. | 36 | 93 | |||
| Y50D7A.4 |
| N-terminal acetyltransferase | H. M. D. | 49 | 100 | |||
| C32E12.3 |
| Osmotic stress response protein | 58 | 97 | ||||
| F37C12.2 |
| p53-mediated apoptosis protein EI24/PIG8 | H. M. D. | 28 | 97 | ▴ | ||
| R04F11.1 |
| Tight junction claudin | 40 | 93 | ||||
| F55B12.4 |
| tRNA nucleotidyltransferase/poly(A) polymerase | H. M. D. | 43 | 98 | |||
| R144.4 |
| WAS/WASL-interacting protein family member 3 | H. M. D. | 7 | 90 | ▴ | ||
| Uncharacterized | ||||||||
| C01G8.6 |
| Unknown | H. | 46 | 92 | |||
| F28B1.1 |
| Unknown | 2 | 86 | ||||
| F29G6.3 |
| Unknown | 42 | 97 | ▾ | |||
| F45H11.3 |
| Unknown | 26 | 94 | ▾ | |||
| T27C4.2 |
| Unknown | 48 | 105 | ||||
| Y47D7A.10 |
| Unknown | 56 | 104 | ||||
| Y50D7A.5 |
| Unknown | 25 | 95 | ||||
| Y54E10A.16 |
| Unknown | 51 | 98 | ||||
| Y61A9LA.9 |
| Unknown | 46 | 94 | ||||
| ZK856.12 |
| Unknown | 48 | 98 | ||||
| C40H5.6 |
| Pseudogene | 46 | 93 | ||||
| F13A7.6 |
| Pseudogene | 50 | 101 | ||||
| T10C6.8 |
| Pseudogene | 31 | 95 | √ | |||
| Y18D10A.18 |
| Pseudogene | 40 | 104 | ||||
The gene names were annotated based on WormBase release WS221. All the previously unnamed genes were named either ttm or hpo based on their phenotypes.
We have published ten genes that upon reduction lead to a Hpo phenotype and knew of one other gene in the p38 pathway (tir-1) that is a strong hpo. Of these 11, three are not in the Ahringer RNAi library (wwp-1, sek-1, pmk-1); one (ire-1), upon RNAi, leads to sickly worms (would have been screened out). Of the remaining seven genes, four have relatively weak to moderate Hpo phenotypes upon knock down (ttm-1, ttm-2, hif-1, and xbp-1) were not found (likely missed due to the lack of sensitivity associated with a genome-wide RNAi experiment). All three of the remaining genes (nsy-1, tir-1, kgb-1) that upon knock down result in a strong Hpo phenotype and are otherwise healthy were identified.
H., M., and D. refer to Homo sapiens, Mus musculus and Drosophila melanogaster, respectively.
d, e: % survivals are relative to empty vector controls.
√ indicates the RNAi clones further confirmed in another round of quadruplicate liquid RNAi assays as shown in Table S1.
“▴” indicates induction by Cry5B and “▾” indicates repression by Cry5B in 3-hour microarray with a 1.5 fold cutoff. DEG = differentially expressed genes.
Figure 2MAPK pathway-dependent transcriptional responses to PFT attack.
(A) Heat-map of PFT-responsive genes in microarray experiments. Cry5B responsive genes with ≥2-fold induction (yellow) or repression (blue) relative to non-treated animals are shown. Brighter shades of color correspond to greater fold changes in expression. Different comparisons of treatments are presented at the top of each column. Wt Cry5B: Fold change in Cry5B-treated/non Cry5B-treated glp-4(bn2) animals. sek-1 Cry5B: Fold change in Cry5B-treated/non Cry5B-treated glp-4(bn2);sek-1(km4) animals. kgb-1 Cry5B: Fold change in Cry5B-treated/non Cry5B-treated glp-4(bn2);kgb-1(um3) animals. sek-1 basal: Fold change in glp-4(bn2);sek-1(km4)/glp-4(bn2) animals (both non Cry5B-treated). kgb-1 basal: Fold change in glp-4(bn2);kgb-1(um3)/glp-4(bn2) animals (both non Cry5B-treated). glp-4(bn2) animals lack a functional germline and have otherwise normal response to Cry5B (see Materials and Methods). Use of these animals removes a major tissue from the animals, allowing for intestinal mRNAs to represent a larger portion of the total RNA population. The values in the parenthesis after the slash indicating the number of the genes in each cluster (I and IV strongly up- or down-regulated; II and III moderately up- or down-regulated), with the values before slash denoting the genes with known PANTHER ontologies. The corresponding enriched PANTHER biological processes and molecular functions are shown in each cluster indicated with Roman numerals. For genes involved in immunity/defense processes, we found 14 in cluster II and 22 in cluster III. (B) Summary of number of genes up- and down-regulated by Cry5B, and their dependence upon KGB-1 and SEK-1. (C) qRT-PCR analysis of selected genes from microarray analysis. Results are the average of three experiments and error bars are standard error of the mean. Each gene behaved in the qRT-PCR experiment as was found in the microarray experiment. In this and other figures, * for P≤0.05, ** for P≤0.01 and *** for P≤0.001.
Figure 3KGB-1 JNK-like MAPK regulates p38-dependent and -independent pathways involved in PFT defenses.
(A) Activation of KGB-1 by Cry5B PFT. Activation was assessed by Western blotting using antibodies specific for phosphorylated and total KGB-1. α-tubulin served as an equal-loading control and phosphorylated p38 MAPK was also tested. Specificity of the antibody was verified by probing kgb-1(um3) mutant animals. The experiment shown is representative of three experiments with similar results. (B) qRT-PCR analysis of known p38 MAPK downstream target genes in response to PFT. All three target genes are regulated by KGB-1. Average of three experiments, error bars are standard error of the mean. (C) In vivo induction of Phsp-4::GFP in the intestine by Cry5B requires KGB-1. The strains Phsp-4::GFP and Phsp-4::GFP;kgb-1(um3) were fed either control E. coli or E. coli expressing Cry5B for 8 hours or shifted to 30°C for 5 hours in the heat shock treatment. Cry5B induces GFP within the intestinal cells of the strain Phsp-4::GFP but not in the strain containing the kgb-1(um3) mutant. General stress induction of Phsp-4::GFP via heat shock is independent of KGB-1. The experiment was performed three times and representative worms are shown. Scale bar is 0.2 mm. (D) Intestinal kgb-1 is required for protection against Cry5B PFT. Intestine-specific knockdown of kgb-1 in VP303 animals are quantitatively hypersensitive to purified Cry5B, compared to empty vector control (L4440). Results are the average of three different experiments; error bars indicate standard error of the mean. (E) qRT-PCR analysis of four KGB-1-dependent hpo genes in response to PFT. All these genes show a KGB-1 dependent/SEK-1 independent induction by Cry5B PFT. Average of three experiments, error bars are standard error of the mean.
LC50 values along with 95% confidence intervals.
| Strain | LC50 (µg/mL) | 95% CI of LC50 | Relative Sensitivity LC50 |
| WT | 10.40 | 9.54–11.34 | |
|
| 0.084 | 0.069–0.101 | 123.8 |
|
| 0.070 | 0.065–0.076 | 148.6 |
Relative sensitivity was calculated by LC50 wild type/LC50 mutant.
Figure 4Intoxication of C. elegans by SLO and the requirement of kgb-1 in protecting C. elegans against SLO.
(A) Viability of wild-type animals is significantly lower than wild-type animals on the mammalian PFT SLO in calcium-free S-medium. In calcium-complete medium, SLO shows a dampened toxicity to wild-type animals. (B) The mammalian PFT SLO mutant, N402, does not intoxicate wile-type C. elegans in calcium-free S-medium. (C) JNK-like MAPK protects against mammalian PFTs. Viability of kgb-1 (um3) loss-of-function animals is significantly lower than wild-type animals on the mammalian PFT SLO in calcium-free S-medium. Results are the average of three different experiments; error bars indicate standard error of the mean.
Figure 5Induction of jun and fos transcripts by Cry5B PFT and specificity of jun-1 in protecting C. elegans against PFTs.
(A) qRT-PCR results showing time-course of induction of jun-1 and fos-1 by Cry5B PFT. (B) Cry5B-induced jun-1 expression is KGB-1 dependent and SEK-1 independent. Data shown were based on 3 hours of PFT treatment. For A and B, three RNA samples independent from each other and from the microarray experiments. (C) Viability of wild-type and jun-1(gk551) animals on three different doses of Cry5B PFT. (D, E) Viability of wild-type and jun-1(gk551) animals on (D) heat stress and (E) P. aeruginosa PA14. For A, B, and C results are the average of at least three different experiments; error bars indicate standard error of the mean. For D and E, the data presented are a single representative from three independent assays. (F) Viability of wild-type and jun-1(gk551) loss-of-function animals on the mammalian PFT SLO and N402 SLO in calcium-free S-medium and calcium-containing S-medium. Results are the average of at least three different experiments; error bars indicate standard error of the mean. (G) Three known p38 MAPK downstream target genes in response to Cry5B-PFT are regulated via JUN-1. Cry5B-induced ttm-2, hsp-4 and spliced xbp-1 expression is JUN-1 dependent. Cry5B-induced ttm-1, kin-18, Y54E5A.1 and F42C5.10 was not attenuated in jun-1 mutant animals. Results are the average of three experiments, and error bars are standard error of the mean.
Figure 6AP-1 protects against mammalian PFTs.
(A) Western blot of mammalian c-JUN in HaCaT cells treated with 125 ng/mL SLO for time indicated. Abbreviations: S: constitutively active version of SLO, N: non-lytic mutant N402 SLO; Co: no-SLO control. (B) HaCaT cells were treated with SLO and biotinylated AP-1 decoy-oligonucleotide (right panel) or biotinylated control oligonucleotide (left panel). Oligonucleotide is stained red (SA-Alexa594), and DNA is stained blue (4',6-diamidino-2-phenylindole/DAPI). The images presented are a single representative from three independent assays. Cells treated with AP-1 decoy show a greater proportion of intoxicated cells with condensed chromosomes, characteristic of becoming pyknotic (e.g., white arrowhead). The proportion of pyknotic cells was quantified as described in the Materials and Methods section; the bar graph shows mean values from three independent experiments (m = mismatched oligonucleotide; AP-1 = AP-1 decoy; error bars: standard error of the mean, P value was determined with paired, one-tailed student's t-test). (C) A model for interconnected regulation of defense to PFT. The KGB-1 JNK-like MAPK regulates both p38 MAPK–dependent (e.g., ttm-1, ttm-2, UPR) and p38 MAPK-independent (e.g., jun-1, kin-18) PFT-induced protection genes. There are also PFT protection genes that, to date, have not been linked to either MAPK pathway.